US 11,925,174 B2
Antibody producing non-human animals
Ton Logtenberg, Driebergen (NL); Rui Daniel Pinto, Utrecht (NL); and Erwin Houtzager, Zeist (NL)
Assigned to Merus N.V., Utrecht (NL)
Filed by Merus N.V., Utrecht (NL)
Filed on Jan. 11, 2018, as Appl. No. 15/868,885.
Application 15/868,885 is a continuation of application No. 13/750,753, filed on Jan. 25, 2013, granted, now 9,951,124.
Application 13/750,753 is a continuation of application No. 12/589,181, filed on Oct. 19, 2009, granted, now 10,966,411.
Application 12/589,181 is a continuation of application No. 12/459,285, filed on Jun. 29, 2009, abandoned.
Claims priority of provisional application 61/133,274, filed on Jun. 27, 2008.
Prior Publication US 2018/0142004 A1, May 24, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/027 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C12N 5/10 (2006.01); C12N 15/85 (2006.01); C07K 14/47 (2006.01); C07K 16/10 (2006.01); C07K 16/12 (2006.01); C07K 16/22 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12P 21/00 (2006.01); G01N 33/569 (2006.01)
CPC A01K 67/0278 (2013.01) [A01K 67/027 (2013.01); A01K 67/0275 (2013.01); C07K 16/00 (2013.01); C07K 16/462 (2013.01); C12N 5/10 (2013.01); C12N 15/8509 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); C07K 14/47 (2013.01); C07K 16/005 (2013.01); C07K 16/10 (2013.01); C07K 16/1282 (2013.01); C07K 16/22 (2013.01); C07K 16/248 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C07K 2317/10 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C12P 21/00 (2013.01); G01N 33/56966 (2013.01)] 6 Claims
 
1. A transgenic murine animal that has been immunized to generate an immune response against an antigen, wherein the genome of said animal comprises a transgene comprising a single human immunoglobulin light chain V gene segment fused to a single human immunoglobulin light chain J gene segment,
such that said fused V/J gene segments encode a rearranged immunoglobulin light chain variable region, wherein the transgene lacks a regulatory element that contributes to somatic hypermutation of the light chain variable region; and
said transgenic animal comprising a population of B cells that secrete a repertoire of antibodies that bind said antigen, said repertoire of antibodies comprising the immunoglobulin light chain variable region encoded by said transgene and a light chain constant region, paired with a diversity of immunoglobulin heavy chains resulting from somatic hypermutation in response to said antigen.